Literature DB >> 29473523

Drug-induced QT Interval Prolongation in the Intensive Care Unit.

Cecilia Villa Etchegoyen1,2, Guillermo Alberto Keller2,3, Sebastian Mrad1, Sixuan Cheng1, Guillermo Di Girolamo1,2.   

Abstract

BACKGROUND: The most common acquired cause of Long QT syndrome (LQTS) is drug induced QT interval prolongation. It is an electrophysiological entity, which is characterized by an extended duration of the ventricular repolarization. Reflected as a prolonged QT interval in a surface ECG, this syndrome increases the risk for polymorphic ventricular tachycardia (Torsade de Pointes) and sudden death.
METHOD: Bibliographic databases as MEDLINE and EMBASE, reports and drug alerts from several regulatory agencies (FDA, EMEA, ANMAT) and drug safety guides (ICH S7B, ICH E14) were consulted to prepare this article. The keywords used were: polymorphic ventricular tachycardia, adverse drug events, prolonged QT, arrhythmias, intensive care unit and Torsade de Pointes. Such research involved materials produced up to December 2017.
RESULTS: Because of their mechanism of action, antiarrhythmic drugs such as amiodarone, sotalol, quinidine, procainamide, verapamil and diltiazem are associated to the prolongation of the QTc interval. For this reason, they require constant monitoring when administered. Other noncardiovascular drugs that are widely used in the Intensive Care Unit (ICU), such as ondansetron, macrolide and fluoroquinolone antibiotics, typical and atypical antipsychotics agents such as haloperidol, thioridazine, and sertindole are also frequently associated with the prolongation of the QTc interval. As a consequence, critical patients should be closely followed and evaluated.
CONCLUSION: ICU patients are particularly prone to experience a QTc interval prolongation mainly for two reasons. In the first place, they are exposed to certain drugs that can prolong the repolarization phase, either by their mechanism of action or through the interaction with other drugs. In the second place, the risk factors for TdP are prevalent clinical conditions among critically ill patients. As a consequence, the attending physician is expected to perform preventive monitoring and ECG checks to control the QTc interval. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adverse drug events; QT-interval prolongation; TdP; electrophysiological entity; intensive care unit; polymorphic ventricular tachycardia

Mesh:

Substances:

Year:  2017        PMID: 29473523     DOI: 10.2174/1574884713666180223123947

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  11 in total

1.  Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.

Authors:  Francis Bessière; Hugo Roccia; Antoine Delinière; Rome Charrière; Philippe Chevalier; Laurent Argaud; Martin Cour
Journal:  JAMA Cardiol       Date:  2020-05-01       Impact factor: 14.676

2.  Death of a young woman with cyclic vomiting: a case report.

Authors:  Ingo von Both; Brittini Santos
Journal:  Forensic Sci Med Pathol       Date:  2021-11-04       Impact factor: 2.007

3.  Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.

Authors:  Francis Bessière; Hugo Roccia; Antoine Delinière; Rome Charrière; Philippe Chevalier; Laurent Argaud; Martin Cour
Journal:  JAMA Cardiol       Date:  2020-09-01       Impact factor: 14.676

Review 4.  Measurement and Management of QT Interval Prolongation for General Physicians.

Authors:  Praveen Indraratna; Daniel Tardo; Madeline Delves; Richard Szirt; Ben Ng
Journal:  J Gen Intern Med       Date:  2019-10-25       Impact factor: 5.128

5.  Development of a Risk Score for QT Prolongation in the Intensive Care Unit Using Time-Series Electrocardiogram Data and Electronic Medical Records.

Authors:  Tae Young Kim; Byung Jin Choi; Yeryung Koo; Sukhoon Lee; Dukyong Yoon
Journal:  Healthc Inform Res       Date:  2021-07-31

6.  Plasma Hyperosmolality Prolongs QTc Interval and Increases Risk for Atrial Fibrillation in Traumatic Brain Injury Patients.

Authors:  Wojciech Dabrowski; Dorota Siwicka-Gieroba; Chiara Robba; Rafael Badenes; Mateusz Bialy; Paulina Iwaniuk; Todd T Schlegel; Andrzej Jaroszynski
Journal:  J Clin Med       Date:  2020-04-30       Impact factor: 4.241

7.  Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.

Authors:  Beatriz Oda Plasencia-García; Gonzalo Rodríguez-Menéndez; María Isabel Rico-Rangel; Ana Rubio-García; Jaime Torelló-Iserte; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

8.  QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.

Authors:  Sok-Sithikun Bun; Philippe Taghji; Johan Courjon; Fabien Squara; Didier Scarlatti; Guillaume Theodore; Delphine Baudouy; Benjamin Sartre; Mohamed Labbaoui; Jean Dellamonica; Denis Doyen; Charles-Hugo Marquette; Jacques Levraut; Vincent Esnault; Sok-Siya Bun; Emile Ferrari
Journal:  Clin Pharmacol Ther       Date:  2020-07-20       Impact factor: 6.903

Review 9.  Advances in the relationship between coronavirus infection and cardiovascular diseases.

Authors:  Mengmeng Zhao; Menglong Wang; Jishou Zhang; Jing Ye; Yao Xu; Zhen Wang; Di Ye; Jianfang Liu; Jun Wan
Journal:  Biomed Pharmacother       Date:  2020-05-13       Impact factor: 7.419

10.  Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.

Authors:  Luigi Moschini; Marco Loffi; Valentina Regazzoni; Giuseppe Di Tano; Elisa Gherbesi; Gian Battista Danzi
Journal:  Heart Vessels       Date:  2020-07-16       Impact factor: 1.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.